Small Cell Lung Cancer Recurrent Clinical Trial
Official title:
A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended phase 2 dose (RP2D) and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the RP2D when administered in combination with carboplatin and etoposide.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03823118 -
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03262454 -
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
|
Phase 2 | |
| Terminated |
NCT02477813 -
Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
|
Phase 2 | |
| Not yet recruiting |
NCT06258642 -
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
|
N/A | |
| Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01441297 -
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03994744 -
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
|
Phase 2 |